The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

KRAS and Outcomes in Pancreatic Cancer

Mark Erlander, PhD
Published Online: 11:58 PM, Tue April 21, 2015
Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.

<<< View more from the 2015 AACR Annual Meeting
 



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.